[Skip to Content]
[Skip to Content Landing]
Citations 0
Editor's Correspondence
May 11, 1998

Cost of Troglitazone Therapy

Arch Intern Med. 1998;158(9):1038. doi:

In reply

Bachman brings up the pertinent issue of the cost of therapy for diabetes. As indicated in Table 3 of our article,1 information on the cost of troglitazone was unavailable at the time of our writing. Current pricing data2 indicate that troglitazone is the most expensive of the available oral antidiabetic agents. Although a cost-benefit analysis3 of interventions for diabetes care entails more than a simple algebraic comparison of the retail cost of individual agents, it is nonetheless disturbing that an efficacious agent may be unavailable to otherwise deserving patients who lack adequate health insurance coverage.